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Atrial septal defects
Tal Geva, Jose D Martins, Rachel M Wald
Atrial septal defects are the third most common type of congenital heart disease. Included in this group of 
malformations are several types of atrial communications that allow shunting of blood between the systemic and the 
pulmonary circulations. Most children with isolated atrial septal defects are free of symptoms, but the rates of exercise 
intolerance, atrial tachyarrhythmias, right ventricular dysfunction, and pulmonary hypertension increase with 
advancing age and life expectancy is reduced in adults with untreated defects. The risk of development of pulmonary 
vascular disease, a potentially lethal complication, is higher in female patients and in older adults with untreated 
defects. Surgical closure is safe and eﬀ ective and when done before age 25 years is associated with normal life 
expectancy. Transcatheter closure oﬀ ers a less invasive alternative for patients with a secundum defect who fulﬁ l 
anatomical and size criteria. In this Seminar we review the causes, anatomy, pathophysiology, treatment, and 
outcomes of atrial septal defects in children and adult patients in whom this defect is the primary cardiac anomaly.
Introduction
Atrial septal defects belong to a group of congenital cardiac 
anomalies that allow communication between the left and 
right sides of the heart. These interatrial communications 
include several distinct defects in the cardiac terminations 
of the systemic and pulmonary veins (sinus venosus and 
coronary sinus defects) and in the interatrial septum 
(atrial septal defects). Patent foramen ovale is a normal 
communication during fetal life and is commonly 
encountered after birth. In this Seminar we review the 
anatomy, pathophysiology, and recent developments in 
the management of interatrial communications in 
children and adults. We focus on haemodynamically 
important atrial septal defects in patients who do not have 
major associated congenital cardiac anomalies.
Incidence and causes
Defects of the atrial septum are the third most common 
type of congenital heart disease, with an estimated 
incidence of 56 per 100 000 livebirths.1 With improved 
recognition of clinically silent defects by echo-
cardiography, recent estimates are about 100 per 
100 000 livebirths.2 About 65–70% of patients with a 
secundum defect, roughly 50% of those with a primum 
atrial septal defect, and 40–50% of those with a sinus 
venosus defect are female.
Most atrial septal defects are sporadic with no identiﬁ able 
cause. Reports of familial clusters of secundum defects 
have noted diﬀ erent modes of inheritance, most notably 
autosomal dominant.3,4 Abnormalities in genes essential to 
cardiac septation have been associated with atrial septal 
defects,5 including mutations in the cardiac transcription 
factor gene NKX2-5,6–8 GATA4 and TBX5,4,9–11 MYH6 located 
on chromosome 14q12,12 and other mutations.13–15 The 
association between secundum defects and conduction 
abnormalities, especially atrioventricular block, has been 
linked to mutations in NKX2-5.16–19 The risk of a secundum 
defect is increased in families with history of congenital 
heart disease, especially when an atrial septal defect is 
present in a sibling.3
Secundum defects are often encountered in genetic 
syndromes such as Holt-Oram, Ellis van Creveld, Noonan, 
Down, Budd-Chiari, and Jarcho-Levine, to mention only a 
few.20–27 In Holt Oram syndrome (NKX2-5 mutation), an 
atrial septal defect is seen in 66% of cases. In patients 
with trisomy 21, secundum and primum defects are the 
most frequent lesions, accounting for 42% and 39% of 
major congenital heart disease, respectively.28
Exposure to several substances has been associated 
with atrial septal defects, including fetal alcohol 
syndrome,29 ﬁ rst trimester maternal cigarette 
consumption,30,31 and some antidepressants.32–34 Other 
maternal risk factors include diabetes, increased dietary 
glycaemic index in women without diabetes,35,36 and 
advanced maternal age (≥35 years).37,38
Developmental considerations
Knowledge of the development of the atrial septum and its 
neighbouring systemic and pulmonary veins forms the 
basis for the classiﬁ cation of interatrial communications. 
Atrial septation involves septum primum, septum 
secundum, and the atrioventricular canal septum. Figure 1 
shows key elements of atrial septation.39–43
Normal development of the atrial septum results in 
formation of the fossa ovalis, which includes two 
anatomical elements: ﬁ rst, muscular boundaries 
contributed by septum secundum; and second, the valve 
of the fossa ovalis, which attaches on the left atrial aspect 
of septum secundum—septum primum. The atrial 
component of the atrioventricular canal septum lies 
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Search strategy and selection criteria
We searched PubMed for articles in English with the term 
“atrial septal defect” in the title from Jan 1, 2003, to 
April 24, 2013. We also searched for multiple combinations 
of the terms “atrial septal defect” AND relevant terms such 
as “pregnancy”, “pulmonary hypertension”, “Eisenmenger 
syndrome”, “arrhythmias”, “outcomes”, “surgery”, “device”, 
“percutaneous”, “gene”. We also retrieved relevant articles 
from the reference list of key articles. Whenever possible, 
we prioritised articles published in the past 5 years, but 
cited older references when appropriate.
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anterior and inferior to the fossa ovalis, separating it 
from the tricuspid and mitral valve annuli—the 
atrioventricular canal septum (ﬁ gure 2). The tissue that 
separates the right pulmonary veins from the superior 
vena cava and from the posterior and inferior aspects of 
the right atrial free wall is termed sinus venosus.44–46 The 
tissue that separates the coronary sinus from the left 
atrium is termed coronary sinus septum.47
Anatomy
Patent foramen ovale
Patent foramen ovale is the space between a well developed 
(valve-competent) septum primum and a normally formed 
septum secundum (ﬁ gure 3). It is a normal interatrial 
communication during fetal life, characterised by 
streaming of oxygen-rich ﬂ ow from the ductus venosus 
and, to a lesser extent, from the inferior vena cava, through 
the foramen ovale to the left atrium. After birth, left atrial 
pressure normally exceeds right atrial pressure and, 
septum primum apposes septum secundum, and the 
foramen ovale narrows. A patent foramen ovale is seen in 
almost all newborn babies, but its frequency decreases 
with advancing age.48–50 Complete anatomical closure of 
the foramen ovale occurs in 70–75% of adults.51
Secundum atrial septal defect
Secundum atrial septal defect is a defect within the fossa 
ovalis usually due to one or several defects within septum 
primum (ﬁ gure 2B). Septum secundum is well-formed 
in most patients. Most secundum defects are not 
conﬂ uent with the vena cavae, right pulmonary veins, 
coronary sinus, or the atrioventricular valves. With the 
exception of patent foramen ovale, secundum atrial 
septal defect is the most common cause of an atrial-level 
shunt. The size of secundum defects varies from several 
millimetres to 2–3 cm. Large defects are usually 
associated with substantial deﬁ ciency, or even complete 
absence, of septum primum.
Primum atrial septal defect
Primum atrial septal defect is one of several variants of 
common atrioventricular canal defects (also termed 
atrioventricular septal defect) with an interatrial 
communication located between the anterior-inferior 
margin of the fossa ovalis and the atrioventricular 
valves. The defect is characterised by a common 
atrioventricular oriﬁ ce with two distinct atrioventricular 
valve annuli completed by valve tissue adhering to the 
crest of the ventricular septum. The atrioventricular 
tissue occludes the space that accounts for the 
ventricular septal defect component in the complete 
form of the malformation (ﬁ gure 2B). In addition to the 
septal defect, the atrioventricular valves in this anomaly 
are almost always abnormal, including a cleft in the 
anterior mitral leaﬂ et. Unlike other types of atrial septal 
defects, the position and course of the conduction axis 
is abnormal as in complete atrioventricular canal defect.
Sinus venosus defect
This defect is a communication between one or more of 
the right pulmonary veins and the cardiac end of the 
superior vena cava (superior vena cava type) or the 
posterior-inferior atrial wall just above the inferior vena 
cava-right atrial junction (inferior sinus venosus defect; 
ﬁ gure 2B).44,46 About 4–11% of atrial septal defects are sinus 
venosus defects.52 The most common location of the 
Figure 1: Development of the atrial septum
(A) At 28 days after gestation, septum primum (Sep 1°)—the ﬁ rst septum to appear in the developing atria—
develops as a crescent-shaped structure. Its leading edge is covered by a layer of mesenchymal cells called 
mesenchymal cap (shown in red). The space between the developing septum primum and the developing 
endocardial cushions is called foramen primum or ostium primum. Septum secundum (Sep 2°; limbus of the fossa 
ovalis) is a crescent-shaped muscular infolding of the atria wall that appears shortly thereafter to the right of 
septum primum. (B) At 35 days, both septum primum and septum secundum continue to develop. The openings 
within septum primum are called foramina secundi. (C) At 60 days, the atrial septum is nearly fully formed and the 
foramina secundi close by way of coalescing fenestrations within septum primum. The foramen ovale remains 
patent throughout pregnancy. Modiﬁ ed from Geva,39 with permission from Wiley-Blackwell Publishing. 
CPV=common pulmonary vein. IVC=inferior vena cava. LA=left atrium. LV=left ventricle. LVV=left venous valve. 
RA=right atrium. RV=right ventricle. RVV=right venous valve. SVC=superior vena cava.
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Figure 2: Anatomy of the atrial septum and neighbouring structures
(A) Right atrial aspect of the normal atrial septum. (B) Types of interatrial communications. Modiﬁ ed from Geva,39 
with permission from Wiley-Blackwell Publishing. ASD=atrial septal defect. Ao=aorta. CS=coronary sinus. CT=crista 
terminalis. EV=Eustachian valve. FO=foramen ovale. IVC=inferior vena cava. RA=right atrial. RLPV=right lower 
pulmonary vein. RMPV=right middle pulmonary vein. RUPV=right upper pulmonary vein. SLB=superior limbic band 
(septum secundum). SVC=superior vena cava. TBV=Thebesian valve.
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defect (around 87%43) is between the right upper 
pulmonary vein and the superior vena cava, resulting 
from deﬁ ciency of the tissue that separates these two 
veins.44,45 The left atrial oriﬁ ce of the right upper pulmonary 
vein allows for communication between the left atrium 
and the cardiac end of the superior vena cava. Less 
frequently, the defect involves the posterior or inferior 
aspects of the right atrium with or without involvement of 
the right lower and middle pulmonary veins (ﬁ gure 2B).44,46
Coronary sinus defect
This uncommon atrial communication results from 
partial or complete unrooﬁ ng of the tissue separating the 
coronary sinus from the left atrium, allowing a shunt 
through the defect and the coronary sinus oriﬁ ce. The 
association of a coronary sinus septal defect and persistent 
left superior vena cava is termed Raghib syndrome.53
Common atrium
Common atrium is present when septum primum, 
septum secundum, and the atrioventricular canal septum 
are absent, which is often seen in patients with heterotaxy 
syndrome. Remnants of atrial septal tissue can sometimes 
be recognised.
Pathophysiology
In most patients an atrial septal defect results in left-to-
right shunt. The direction and magnitude of blood ﬂ ow 
through an atrial communication are determined by the 
size of the defect and by the relative atrial pressures, 
which relate to the compliances of the left and right 
ventricles. Both the size of the defect and the compliances 
of the ventricles can change over time.54 At birth, 
pulmonary vascular resistance is high and right 
ventricular compliance is low, changing gradually to a 
high compliance–low resistance circulation. The usual 
haemodynamic ﬁ ndings in secundum atrial septal 
defect include left-to-right shunt mostly during late 
ventricular systole and early diastole, increasing during 
atrial contraction and expiration. Most defects smaller 
than 10 mm in diameter are associated with a fairly 
small shunt and minimum or no enlargement of the 
right heart structures. In larger defects the pulmonary-to-
systemic ﬂ ow ratio can exceed 1·5 and triggers a cascade 
of changes in the myocardium and in the pulmonary 
vasculature. The initially predominant volume overload 
and later pressure overload on the right heart leads to 
chamber enlargement with diastolic septal shift towards 
the left ventricle and adverse interventricular interaction 
resulting in decreased left ventricular compliance and a 
shift from a circular to a D-shape short-axis geometry.55 
These changes result in decreased left ventricular 
diastolic ﬁ lling, increased pulmonary-to-systemic ﬂ ow 
ratio through the defect, and diminished systemic 
output. Left ventricular systolic dysfunction can develop 
late in patients with a large atrial septal defect.56 Factors 
that decrease left-to-right ﬂ ow include anatomical (eg, 
valve or vessel stenosis) or functional (eg, pulmonary 
vascular disease) reasons.
A longstanding shunt results in impaired right atrial 
reservoir and pump functions,57 right ventricular 
dilatation, myocardial cell hypertrophy and ﬁ brosis, 
and  cellular injury manifesting as increased serum 
concentrations of cardiac troponin-I.58 The pulmonary 
vascular bed remodels with myointimal cell proliferation, 
increased medial smooth muscle, and increased collagen 
leading to arteriolar narrowing and pulmonary hyper-
tension. Mild increase in pulmonary artery pressure is 
common in young patients with a large atrial septal 
defect, but a few (6–19%), mostly female patients, will 
develop pulmonary vascular disease over time.59,60
Natural history
Defect size
The natural history of isolated atrial communications 
varies according to anatomical type, size, and patient-
speciﬁ c factors. Sinus venosus and primum defects are 
usually associated with a haemodynamically signiﬁ cant 
shunt, do not decrease in size, and usually need surgical 
closure. By contrast, the natural history of secundum 
defects vary widely. Spontaneous closure occurs 
frequently in young patients with small defects. Hanslik 
and colleagues,61 in a study of 200 consecutive patients 
(median age at presentation 5 months; median follow-
up 4·5 years), reported spontaneous closure in 56% of 
patients with an initial defect size of 4–5 mm, 30% in 
Figure 3: Atrial septal components and patent foramen ovale
Arrow indicates patent foramen ovale (PFO). Modiﬁ ed from Geva,39 with permission from Wiley-Blackwell 
Publishing. AVS=atrioventricular septum. FO=fossa ovalis. ILB=inferior limbic band. LA=left atrium. LV=left ventricle. 
RA=right atrium. RV=right ventricle. Sep 1°=septum primum. SLB=superior limbic band (septum secundum).
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6–7 mm defects, 12% in 8–10 mm defects, and in none 
of those with a larger defect. In that study, 39% of 
patients diagnosed at younger than 1 year had 
spontaneous closure by contrast with only 19% of those 
diagnosed later.
In patients whose secundum defect does not close 
spontaneously, defect size can increase or decrease with 
age.61–64 In general, 70% of initially small (≤4 mm) defects 
decrease in size, 12% remain unchanged, and 18% increase. 
By contrast, in those with an initial defect size greater than 
8–12 mm, only 9% decreased in size, 15% remain 
unchanged, and 76% increased. Notably, most reports of 
change in defect size have reported absolute values. 
Whether changes in defect size are proportional to increase 
in heart size or to somatic growth is unclear.
Clinical presentation
Most patients remain asymptomatic throughout most of 
childhood. Even those with a large left-to-right shunt might 
not have overt symptoms until adulthood. Incidental 
diagnosis by an echocardiogram obtained because of a 
heart murmur or an abnormal ﬁ nding on a chest 
radiogram or an electrocardiogram is common. Rarely an 
isolated atrial septal defect is found in an infant with 
tachypnoea, slow weight gain, or recurrent respiratory 
infections.65,66 In such cases, a careful search for associated 
non-cardiac anomalies and pulmonary hypertension 
should be done.67 In the second decade of life, none or 
subtle symptoms of shortness of breath with exertion or 
palpitations are common. By contrast, most adult patients 
with a large defect present with symptoms, including 
fatigue, exercise intolerance, palpitations, syncope, 
shortness of breath, peripheral oedema, manifestations of 
thromboembolism, and cyanosis.
Exercise capacity
Exercise intolerance is uncommon in young children with 
an isolated atrial septal defect.68 Nonetheless, pulmonary 
function is often impaired in this age group.69 The frequency 
of exercise intolerance increases insidiously with age. 
Exercise capacity and peak oxygen consumption are 
decreased in most adults with unrepaired secundum defect, 
often at 50–60% of predicted values in healthy controls.70
Arrhythmias
Major arrhythmias are uncommon in children with atrial 
septal defects. The most common arrhythmias are atrial 
ﬂ utter and ﬁ brillation, incidences of which increase with 
age. Among the 211 adult patients with atrial septal defects 
reported by Berger and colleagues,71 only one patient 
younger than 40 years had atrial ﬂ utter compared with 15% 
of the patients aged 40–60 years; 16% and 19% had atrial 
ﬂ utter and ﬁ brillation, respectively, in those older than 
60 years. In addition to tachyarrhythmias, atrioventricular 
block associated with genetic mutations (eg, NKX2-5) has 
been reported.16,72
Pulmonary hypertension
Pulmonary hypertension is uncommon in children with 
an isolated atrial septal defect. In adults with large 
defects, mild or moderate pulmonary hypertension is 
common and tends to increase with age and in those 
living at high altitude.73–75 Pulmonary vascular obstructive 
disease with or without right-to-left atrial-level shunting 
(Eisenmenger syndrome) is present in 5–10% of adults 
with untreated atrial septal defects, with a female-to-male 
ratio of roughly 2.59,60 Patients with atrial septal defect and 
severe pulmonary hypertension are diagnosed at a 
Figure 4: Echocardiographic imaging of atrial defects
(A) Secundum atrial septal defect in the centre of the fossa ovalis (*). Note the left-to-right ﬂ ow imaged by colour 
Doppler (arrow). (B) Superior vena cava (SVC)-type sinus venosus defect located above the fossa ovalis between 
the SVC and the right upper pulmonary vein as it enters the left atrium (LA). RA=right atrium. RPA=right 
pulmonary artery.
A
B
LA
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*
LA
RPA
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RA
*
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median age of 51 years, which is several decades older 
than those with an underlying ventricular septal defect.76 
The pathophysiology of pulmonary vascular obstructive 
disease is not fully understood and contributing factors 
such as Down syndrome, other genetic predisposition, 
upper airway obstruction, pulmonary emboli or in-situ 
pulmonary artery thrombosis, and drug use such as 
anorexigenic agents (eg, fenﬂ uramine) should be 
explored, especially in patients with fairly small defects.
Life expectancy
The availability of surgical closure of atrial septal defects 
since 1952 hampers the evaluation of its natural history in 
the modern era. Nonetheless, evidence clearly suggests 
that untreated large secundum defects are associated with 
a reduced lifespan. Campbell reported a low annualised 
mortality rate in the ﬁ rst two decades of life (0·6% and 
0·7% per year, respectively), increasing to 4·5% per year 
in the fourth decade and 7·5% per year in the sixth 
decade.77 This ﬁ nding is supported by a subsequent study 
comparing early versus late defect closure.78
Diagnosis
Clinical
On physical examination, most young patients with an 
isolated secundum atrial septal defect are acyanotic and 
can have few or no symptoms. The precordium is often 
hyperdynamic to palpation. The second heart sound is 
characteristically widely split without respiratory 
variations. The intensity of the pulmonary component of 
the second heart sound (P2) corresponds to the pulmonary 
artery pressure with a loud sound indicating pulmonary 
hypertension. A soft systolic ejection murmur is usually 
heard over the pulmonary area in the left upper sternal 
border. A diastolic rumble over the left lower sternum 
corresponds to increased ﬂ ow through the tricuspid 
valve. A holosystolic ﬂ ow murmur over the apex 
indicative of mitral regurgitation should raise suspicion 
for a primum atrial septal defect or mitral valve prolapse. 
Signs of right heart failure are rare, but can be 
encountered in adults with pulmonary hypertension.
Electrocardiography
Characteristic electrocardiographic features of atrial 
septal defect include a tall P wave indicative of right atrial 
enlargement, incomplete right bundle branch block 
pattern, and right axis deviation. The rhythm is typically 
sinus, but in adult patients can be atrial ﬂ utter or 
ﬁ brillation. Right ventricular hypertrophy is evident in 
patients with pulmonary hypertension. Left axis deviation 
with a superior axis is suggestive of primum defect.
Chest radiography
Enlargement of the right heart structures are evident on 
chest radiography in patients with haemodynamically 
signiﬁ cant atrial septal defects. Right atrial and 
pulmonary artery enlargement are best seen in the 
anterior-posterior projection whereas right ventricular 
enlargement is best seen in the lateral projection. 
Similarly, left atrial dilatation (associated with mitral 
regurgitation in primum defects) is evident in the lateral 
projection. The pulmonary vasculature is prominent. 
Discrepancy between enlarged central pulmonary 
arteries and relative paucity of peripheral vasculature 
suggests pulmonary vascular obstructive disease.
Echocardiography
Transthoracic echocardiography is the primary diagnostic 
method for determining the presence, location, size, and 
haemodynamic characteristics of atrial septal defects. 
Two-dimensional imaging with colour Doppler ﬂ ow 
mapping depicts the location and size of the defect and 
the direction of ﬂ ow (ﬁ gure 4). Spectral Doppler further 
documents the direction of ﬂ ow and allows determination 
of ﬂ ow velocity. Three-dimensional imaging allows en-
face views of the defect from the right and left atrial 
perspectives, allowing appreciation of the defect’s shape 
and change in size during the cardiac cycle (ﬁ gure 5).79 
The haemodynamic burden associated with the defect is 
determined by assessments of right atrial, right 
ventricular, and pulmonary artery size. Right ventricular 
and pulmonary artery pressures can be estimated by 
Doppler determination of the velocities of the tricuspid 
and pulmonary valve regurgitation jets. The former 
estimates the peak systolic pressure diﬀ erence between 
the right ventricle and right atrium whereas the latter 
estimates the early and late pressure diﬀ erences between 
the main pulmonary artery and right ventricle, which 
correlate with the mean and diastolic pulmonary artery 
pressures. The geometry of the interventricular septum 
is another indicator of right ventricular volume and 
pressure overloads. Right ventricular volume overload 
manifests as diastolic septal ﬂ attening (deviation towards 
the left ventricle) and pressure overload manifests as 
septal ﬂ attening during systole.
Figure 5: Three-dimensional imaging of a secundum atrial septal defect imaged by a transoesophageal 
echocardiogram before (A) and after (B) device closure
(A) En-face view of the defect as seen from the right atrium. (B) En-face view of the occluding device as seen from 
the left atrium. Images are from diﬀ erent patients. Ao=ascending aorta. ASD=atrial septal defect. IVC=inferior vena 
cava. SVC=superior vena cava. TV=tricuspid valve.
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The diagnostic sensitivity of transthoracic echo-
cardiography is excellent in young patients, but lower in 
those with restricted acoustic windows due to obesity, 
large body habitus, and previous thoracic surgery. 
Transoesophageal echocardiography provides an 
excellent alternative approach in these patients and is 
also used for guidance of transcatheter closure.
Contrast echocardiography with injection of agitated 
saline through a peripheral venous cannula during 
imaging of the atria and ventricles can assist in the 
diagnosis of atrial septal defect, especially in patients 
with restricted acoustic windows.80 In the presence of a 
left superior vena cava, injection of agitated saline in a 
left arm venous cannula can diagnose a coronary sinus 
septal defect with appearance of the contrast in the left 
atrium before it appears in the right atrium.
MRI and CT
Advances in cardiac MRI techniques allow anatomical 
delineation of atrial septal defects and quantitative 
assessment of their haemodynamic consequences.81,82 
Speciﬁ cally, cine steady-state free precession imaging is 
currently the gold standard technique for measurements 
of ventricular volumes and function whereas phase velocity 
ﬂ ow mapping allows accurate quantiﬁ cation of the 
pulmonary-to-systemic ﬂ ow ratio.83 Magnetic resonance 
angiography allows imaging of associated pulmonary and 
systemic venous anomalies. In patients with isolated 
secundum or primum defects, cardiac MRI is seldom 
necessary. Exceptions include those in whom the location 
of the defect or its haemodynamic burden is in question. 
In contrast, cardiac MRI is an important diagnostic 
method in sinus venosus defects (ﬁ gure 6).46,84 The 
posterior location of these defects and the frequently 
associated anomalous pulmonary venous drainage hamper 
the ability of transthoracic echocardiography to adequately 
evaluate these defects as patients’ body size increases.
High-resolution contrast CT is capable of anatomical 
delineation of atrial septal defects. However, the risk of 
cancer related to ionising radiation limits its application 
to only carefully selected patients in whom other 
modalities are insuﬃ  cient.85
Diagnostic catheterisation
Cardiac catheterisation is seldom done solely for diagnostic 
purposes. Most catheterisations are done with the 
intention to close the defect percutaneously. A diagnostic 
procedure typically precedes device placement, including 
determination of pressures and pulmonary and systemic 
ﬂ ow ratios. In selected patients, angiography is done to 
delineate associated anomalies not shown by non-invasive 
imaging. In adult patients at risk of coronary artery disease 
and in those with pulmonary hypertension, diagnostic 
catheterisation is indicated for detailed evaluation.
Treatment
Indications and contraindication for defect closure
Closure of an atrial septal defect is indicated in the 
presence of a haemodynamically signiﬁ cant shunt that 
causes enlargement of right heart structures, irrespective 
of symptoms (class I, level of evidence B).86,87 Before the 
advent of non-invasive imaging, a haemodynamically 
signiﬁ cant shunt was classically deﬁ ned by a pulmonary-
to-systemic ﬂ ow ratio greater than 1·5, which is the 
magnitude of shunt needed for a right-sided volume 
overload and pulmonary overcirculation. Other 
indications include suspicion of paradoxical embolism 
in the absence of other causes (class IIa, level of 
evidence C) or in the rare instance of documented 
orthodeoxia-platypnoea (dyspnoea and hypoxaemia 
accompanying a change to a sitting or standing from a 
recumbent position) irrespective of shunt size.86 A small 
defect without evidence of volume overload on the right 
heart and without other indications should be followed 
up expectantly, keeping in mind the possibility of 
increase in shunt later in life.
Pulmonary hypertension is not an absolute contra-
indication for defect closure. American and European 
practice guidelines86,87 state that an atrial septal defect can 
be closed if the pulmonary vascular resistance is lower 
than two-thirds of the systemic vascular resistance (at 
baseline or after pulmonary vasodilator acute challenge 
or targeted pretreatment course) and there is evidence of 
a pulmonary-to-systemic ﬂ ow ratio greater than 1·5 
(class IIB, level of evidence C). A calculated pulmonary 
vascular resistance greater than 8 Woods units generally 
precludes closure, as does a resting interatrial right-to-
left shunt such as Eisenmenger syndrome.88 Closure can 
also be contraindicated in other conditions in which the 
defect serves as a decompressing route for blood ﬂ ow 
Figure 6: Inferior sinus venosus defect imaged by cardiac MRI
(A) Cine steady-state free precession image in an oblique sagittal plane showing the defect in the posterior-inferior 
atrial junction (arrow), just above the entrance of the inferior vena cava (IVC) to the right atrium (RA). Note that 
the fossa ovalis is intact (arrow head). (B) Phase velocity mapping in the same orientation showing ﬂ ow from the 
left atrium (LA) to the right atrium through the defect. SVC=superior vena cava.
A B
LA
RA
IVC
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(pop-oﬀ  valve), including severe obstructive or restrictive 
right or left heart lesions.87,89 Patients with pulmonary 
hypertension need careful evaluation in an experienced 
centre, including possible balloon occlusion of the defect 
with haemodynamic assessment.
Timing of defect closure
A haemodynamically signiﬁ cant atrial septal defect 
should be closed electively once the diagnosis is 
conﬁ rmed. Although there is no lower limit of age for 
defect closure, many clinicians choose to refer 
asymptomatic children for the procedure at age 
3–5 years. At the other end of the age spectrum, evidence 
indicates that with the exception of the contraindications 
noted above, defect closure is safe and eﬀ ective in 
improving symptoms, even in elderly patients.74,89–91
Treatment strategies for defect closure
Sinus venosus, primum, and coronary sinus septal 
defects need surgical closure. Secundum defects can be 
closed by either surgery or by a percutaneous route 
using an occluding device delivered by a catheter. 
Transcatheter closure might not be feasible in some 
large secundum defects or small infants.
Surgery
Since the pioneering reports of Murray who ﬁ rst closed an 
atrial septal defect without direct visualisation in 1948 and 
Lewis and Tauﬁ c who used hypothermia and inﬂ ow 
occlusion to close an atrial septal defect under direct vision 
in 1952,92,93 more than 50 years of experience have resulted 
in a safe and eﬀ ective operation with almost no mortality 
and little morbidity. The defect is closed under direct vision 
using cardiopulmonary bypass, either by direct suture or 
with a pericardial or a synthetic patch. Access to the heart 
is accomplished through median sternotomy, sub-
mammary incision, lateral thoracotomy, transxiphoid, and 
other approaches. A small skin incision improves the 
cosmetic results and video-assisted thoracoscopic 
techniques have been shown to be feasible.94
Results of secundum defect closure in the modern era 
are excellent with near-zero mortality for isolated 
defects. Morbidities such as arrhythmias, bleeding, 
pneumothorax, and pericardial and pleural eﬀ usions 
are usually transient. Arrhythmia and prolonged stay in 
the intensive care unit (>3 days) are more common in 
adults, especially elderly patients.91 The long-term 
results of surgical closure of secundum defects are 
excellent for patients operated on when younger than 
25 years with an actuarial survival curve that is 
indistinguishable from that of the general 
population—98% versus 99% in those operated on 
when younger than 12 years and 93% versus 97% in 
those operated on between the ages of 12 and 24 years. 
By contrast, those operated on at age 25–41 years 
(84% vs 91%) and older than 41 years (40% vs 59%) had 
lower survival than healthy individuals.78
Transcatheter closure
Since King and colleagues95 reported the ﬁ rst transcatheter 
device closure of a secundum defect in 1976 the ﬁ eld has 
evolved substantially with a range of occluding devices and 
delivery systems now available (table). Improvements in 
device design and ease of use coupled with avoidance of 
cardiac surgery have led many centres to adopt 
transcatheter closure of secundum defects as their ﬁ rst 
choice.86,87,96 Secundum defects larger than 36–40 mm in 
maximum diameter, inadequate margins to anchor the 
device, and interference of the device with atrioventricular 
valve function or with systemic or pulmonary venous 
drainage are generally regarded as relative contra-
indications.97,98 The device is typically introduced through a 
sheath in the femoral vein and its deployment is guided by 
a combination of ﬂ uoroscopy and echo cardiography. 
Echocardiographic guidance can be accomplished through 
a transoesophageal approach (real-time two-dimensional 
and three-dimensional), intracardiac ultrasound, or 
transthoracic imaging.99,100 Most practitioners prescribe 
antiplatelet drugs after device implantation, but data to 
support the practice are lacking.
Current results of device closure of secundum defects 
show a good safety and eﬃ  cacy proﬁ le. A retrospective 
multicentre review of 478 patients undergoing implantation 
of an Amplatzer septal occluding device (St Jude Medical, 
Plymouth, MN, USA) at a median age of 6 years showed 
technical success in 96% with an occlusion rate at 24 h of 
99·6%.101 A study in 650 adult patients at a mean age of 
45 years showed similarly good early results.102 Results of a 
prospective multicentre cohort evaluating the Helex device 
(W L Gore & Associates, Flagstaﬀ , AZ, USA) showed a 
procedural success rate of 93% and closure rate of 98·1%.103
Complications occur in inverse relation to institutional 
procedural volume.104 The rates of minor and major 
complications have been reported at roughly 5% and 1%, 
respectively.101,102,105 Meta-analysis of 142 case series showed 
major periprocedural complications in 1·6% (95% CI 
1·4–1·8), with device embolisation necessitating surgery 
(0·7%) and pericardial tamponade (0·1%) being the most 
common.106 The most common minor complications 
were atrial arrhythmias, vascular complications, and 
transient heart block. Late complications included atrial 
arrhythmias (1·5%), stroke (0·4%), device thrombosis 
(0·2%), device erosion through the atrial wall or aortic 
root (0·1%), device embolisation (0·1%), and death 
(0·1%). Cardiac erosion by the device was the focus of 
several reports107–109 and a review by the US Food and 
Drug Administration.110 New-onset or worsening 
migraine headache have been reported in some patients, 
some of whom were later found to have an allergy to 
nickel, which is a component of some devices.111 
Antiplatelet treatment with clopidogrel was found in that 
report to be helpful in amelioration of the headaches.
Although several studies have compared costs, clinical 
outcomes, eﬃ  cacy, and rates of complications between 
transcatheter and surgical closure of secundum 
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defects,91,112–114 no prospective randomised trial has been 
published at the time of writing. In general, these studies 
have shown no major advantage of one approach compared 
with the other with each having speciﬁ c advantages and 
disadvantages.114 The aforementioned discussion 
emphasises the importance of long-term follow-up after 
defect closure.
Clinical and haemodynamic results of defect closure
Patients commonly report subjective improvement in 
symptoms after closure of atrial septal defects.70,89 In 
young children, somatic growth rate can increase.115 Some 
studies have shown an increase in exercise capacity in 
adults after defect closure,116 but in asymptomatic children 
the change has been minimum or none.68 Conversely, 
studies on respiratory symptoms and pulmonary function 
in children have shown a signiﬁ cant improvement after 
closure.117,118
The haemodynamic response to defect closure includes 
reduction in right atrial and right ventricular size.119–122 
Most of the decrease occurs immediately with some 
further remodelling 1–2 years later.119 A younger age at 
closure and a lesser degree of chamber enlargement before 
repair are associated with a higher likelihood of 
normalisation of right ventricular size.119 Persistent 
enlargement of the right heart has been reported in up to a 
third of patients, mostly in adults with severely dilated 
chambers.121 Echo cardiographic indices of right ventricular 
function before and after defect closure have shown mixed 
results with some measures showing an improvement 
from before to after closure, whereas others show either no 
change or a decrease.120,123,124 Left ventricular ﬁ lling improves 
in children and young adults.120 However, in adults with 
pre-existing decreased left ventricular compliance, the 
acute increase in preload associated with defect closure 
can lead to worsening left atrial and pulmonary venous 
hypertension and heart failure symptoms.125 Pulmonary 
artery pressure decreases to normal except in some 
patients with moderate to severe pulmonary 
hypertension.126
A salutary eﬀ ect of defect closure on atrial arrhythmias 
has been shown in meta-analysis of 26 studies spanning 
four decades, including 1841 surgical closures and 
945 transcatheter closures.127 Considering all studies, the 
incidence of atrial arrhythmias decreased in the short term 
(odds ratio 0·66, 95% CI 0·57–0·77). However, when only 
studies with at least 5 years of follow-up were considered, 
the beneﬁ cial eﬀ ect was lost. Other studies have identiﬁ ed 
persistent rhythm and conduction abnormalities 
associated with delayed closure.128,129 These observations 
have led the American Heart Association and the European 
Society of Cardiology to consider a Maze antiarrhythmic 
procedure in selected adult patients.86,87
Adults with atrial septal defects
Unrepaired defects
An isolated atrial septal defect can occasionally go 
undiagnosed for decades. It accounts for 25–30% of 
congenital heart disease cases diagnosed in adulthood.130 
Although many young adults have no subjective 
symptoms, exercise testing usually unveils subnormal 
exercise capacity.131 With advancing age, however, overt 
symptoms of fatigue, exercise intolerance, shortness of 
breath, palpitations, and manifestations of heart failure 
become prevalent and survival rate is reduced.77 Onset of 
ischaemic heart disease and other comorbidities associated 
Company Design Maximum 
size of defect
Advantages Disadvantages Regulatory 
status
Amplatzer 
septal occluder
St Jude Medical, 
Plymouth, MN, 
USA
Nitinol mesh of self-
centring double disc with 
polyester patch inside
40 mm Easy to use; versatile; easily withdrawn and 
redeployable; small delivery sheath (8/9 Fr for 
18 mm device); largest experience worldwide
Avoid in nickel allergy; late erosions (rare); stiﬀ er 
delivery cable (distorts anatomy before release) 
and framework (distorts atrial anatomy)
FDA and CE 
mark approval
Gore Helex 
septal occluder
W L Gore & 
Associates, 
Flagstaﬀ , AZ, 
USA
Nitinol helix spiral guide 
covered with ePTFE 
membrane
18 mm Flexible, compliant (no erosion, conforms to 
atrial septal anatomy); low proﬁ le; metal 
almost completely covered by ePTFE; 
retrievable at any stage (even after release); 
experience worldwide
Not self-centred; slightly more challenging 
deployment; care with deﬁ cient rims; more 
device embolisation and residual shunt; needs 
larger sheath (12 Fr for closure of 18 mm defect)
FDA and CE 
mark approval
Figulla atrial 
septal defect 
occluder
Occlutech, 
Helsingborg, 
Sweden
Nitinol mesh of self-
centring double disc with 
Dacron patch inside
40 mm Same as Amplatzer device, but left atrial 
component ﬂ at and latest generation has 
tilting of attachment with delivery cable 
(allows better positioning before release)
Same as Amplatzer device, but needs slightly 
larger sheaths (10 Fr for 18 mm device); less 
published experience
CE mark 
approval
Cera atrial septal 
defect occluder
Lifetech 
Scientiﬁ c, 
Shenzhen, 
China
Nitinol mesh of self-
centring double disc with 
polyester patch inside
42 mm Same as Amplatzer device, but has a ﬂ at left 
atrial component and latest generation has 
tilting with delivery cable (allows better 
positioning before release)
Same as Amplatzer device, but needs slightly 
larger sheaths (10 Fr for 18 mm device); scarce 
published experience
CE mark 
approval
Ultrasept atrial 
septal defect 
occluder
Cardia, Eagen, 
MN, USA
Nitinol double disk self-
centring frame covered 
with polyvinyl alcohol
34 mm Low proﬁ le, ﬂ exible (conforms to atrial 
anatomy), retrievable and re-deployable, 
less metal, which is covered
Requires only slightly larger delivery sheath 
than Amplatzer device (9 Fr for 18 mm device); 
no published experience with newest design, 
only personal communications
CE mark 
approval
See appendix for images of devices. FDA=US Food and Drug Administration. CE=Conformité Européenne. ePTFE=expanded polytetraﬂ uoroethylene.
 Table: Examples of devices for transcatheter closure of atrial septal defect
See Online for appendix
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with decreased left ventricular compliance (eg, essential 
hypertension, aortic valve stenosis, ageing) lead to 
increased left-to-right shunting across the defect, which 
further aggravate the symptoms and lead to clinical 
deterioration. Atrial ﬂ utter and ﬁ brillation are important 
causes of morbidity, seen in 21% of adults older than 
40 years with a rising frequency over time.132
Repaired defects
Irrespective of technique, closure of atrial septal defects 
after age 40 years confers morbidity and mortality 
beneﬁ ts compared with medical therapy alone.132,133 
Studies have shown improvements in symptoms and 
exercise capacity, decrease in right atrial and right 
ventricular size, and improvement in pulmonary 
hypertension in most but not all patients.74,75,121,134,135 
Although these beneﬁ ts are less pronounced after age 
60 years,74,75 symptomatic improvement and increase in 
6 min walking distance coupled with a low procedural 
risk provide the rationale for defect closure in elderly 
patients.74,89,136 In view of the risk of unmasking left 
ventricular diastolic dysfunction by closing an atrial 
communication, test occlusion in the catheterisation 
laboratory is recommended before closure of the defect. 
The risk of atrial tachyarrhythmias, especially atrial 
ﬂ utter and ﬁ brillation, remains high after defect closure 
in adulthood. Risk factors include atrial arrhythmia 
before closure and age at closure older than 40 years.137,138
Pregnancy
Maternal complications are uncommon in isolated atrial 
septal defects not complicated by pulmonary 
hypertension.139 Yap and colleagues140 found similarly low 
rates of maternal complications in women with repaired 
and unrepaired defects, including arrhythmias (4%) and 
transient ischaemic attack (1%). None of the 98 women 
with 188 pregnancies had a stroke, heart failure symptoms, 
or endocarditis. Pre-pregnancy history of arrhythmia and 
maternal age older than 30 years were risk factors for 
maternal cardiac complications. By comparison with the 
general population, women with unrepaired atrial septal 
defects had an increased risk of pre-eclampsia, fetal loss, 
and low birthweight. By contrast, the outcome for oﬀ spring 
of women with a repaired defect was similar to that of the 
general population.
Pregnancy should be avoided in women with an atrial 
septal defect and severe pulmonary hypertension. In a 
contemporary study maternal mortality was prohibitively 
high (28%) in women with congenital heart disease and 
pulmonary hypertension, despite use of pulmonary 
vasodilator therapy in more than half of the patients.141 
Maternal deaths tended to occur shortly after delivery and 
were often caused by heart failure, thromboembolism, 
pulmonary hypertensive crisis, and sudden cardiac death.
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